natgillin/translations-raw huggingface dataset:
Infections and infestations upper respiratory tract infection common common common common common bronchitis common sinusitis uncommon uncommon uncommon uncommon uncommon 
Infekcijske in parazitske bolezni okužba zgornjih dihal bronhitis sinuzitis občasni občasni občasni občasni
Glustin contains lactose monohydrate 
Zdravilo Glustin vsebuje laktozo monohidrat
Glustin 15 mg tablets Glustin 30 mg tablets Glustin 45 mg tablets 
IME ZDRAVILA Glustin 15 mg tablete Glustin 30 mg tablete Glustin 45 mg tablete
- The active substance in Glustin is pioglitazone. 
Zdravilna učinkovina zdravila Glustin je pioglitazon.
Frequency of adverse reactions of pioglitazone by treatment regimen Monotherapy 
Pogostnost neželenih učinkov pioglitazona glede na režim zdravljenja
Glustin may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar. 
Zdravilo Glustin se lahko uporablja kot samostojno zdravilo pri bolnikih, ki ne morejo jemati metformina, in ko zdravljenje z dieto in s telesno vadbo ni uspešno pri nadzoru krvnega sladkorja.
common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness uncommon (may affect up to 1 in 100 people) - inflammation of the sinuses (sinusitis) - difficulty sleeping (insomnia) 
pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) okužba dihal motnje vida povečanje telesne mase odrevenelost občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - vnetje sinusov (sinuzitis)
If you experience this side effect, talk to your doctor as soon as possible. 
Če opazite ta neželeni učinek, se čim prej posvetujte z zdravnikom.
Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible. 
Prav tako se čim prej posvetujte z zdravnikom, če ste imeli zamegljen vid že prej, pa se vam je stanje poslabšalo.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years. 
V skupni analizi neželenih učinkov zlomov kosti iz randomiziranih, kontroliranih, dvojno slepih kliničnih preskušanj pri več kot 8.100 s pioglitazonom in 7.400 s primerjalnim zdravilom zdravljenimi bolniki, ki so se zdravili do 3,5 let, so opazili povečano incidenco zlomov kosti pri ženskah.
Allergic reactions have been reported with frequency not known (cannot be estimated from the available data) in patients taking Glustin. 
Pri bolnikih, ki so jemali zdravilo Glustin, so poročali o alergijskih reakcijah z neznano pogostnostjo (iz razpoložljivih podatkov je ni mogoče oceniti).
- you are breast-feeding or if you are planning to breast-feed your baby. 
če dojite ali nameravate dojiti.
Neoplasms benign, malignant and unspecified (including cysts and polyps) 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) rak sečnega mehurja občasni občasni občasni občasni
Nervous system disorders hypo-aesthesia common common common common common headache common uncommon dizziness common insomnia uncommon uncommon uncommon uncommon uncommon 
Bolezni živčevja hipestezija glavobol občasni omotica nespečnost občasni občasni občasni občasni
Glustin tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. 
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these. 
rifampicin (uporablja se za zdravljenje tuberkuloze in drugih okužb) Obvestite zdravnika ali farmacevta, če jemljete katero od teh zdravil.
Localised swelling (oedema) has also been experienced very commonly (may affect more than 1 in 10 people) in patients taking Glustin in combination with insulin. 
Pri bolnikih, ki so jemali zdravilo Glustin v kombinaciji z insulinom, so zelo pogosto (pri več kot 1 od 10 bolnikov) poročali o lokalnem otekanju (edemih).
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Glustin. 
Pri bolnikih, ki so jemali zdravilo Glustin, so občasno (pri največ 1 od 100 bolnikov) poročali o pojavu raka sečnega mehurja.
Glustin 30 mg 
PODATKI V BRAILLOVI PISAVI Glustin 30 mg
How to store Glustin 
Shranjevanje zdravila Glustin
Glustin 30 mg tablets are white to off-white, round, flat tablets marked “30” on one face, “AD4” on the other. 
Tablete zdravila Glustin 30 mg so bele do sivobele barve, okrogle, ploščate, z oznako “30” na eni in “AD4” na drugi strani.
- Glustin 45 mg tablets are white to off-white, round, flat tablets marked “45” on one face, “AD4” on the other. 
Tablete zdravila Glustin 45 mg so bele do sivobele barve, okrogle, ploščate, z oznako “45” na eni in “AD4” na drugi strani.
Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. 
Pri bolnikih s sladkorno boleznijo tipa 2 se izboljša urejenost glikemije tako na tešče kot po obrokih.
EU/1/00/151/003 EU/1/00/151/004 EU/1/00/151/005 EU/1/00/151/006 EU/1/00/151/007 EU/1/00/151/008 EU/1/00/151/009 EU/1/00/151/010 EU/1/00/151/011 EU/1/00/151/012 EU/1/00/151/013 EU/1/00/151/014 EU/1/00/151/015 EU/1/00/151/016 EU/1/00/151/017 EU/1/00/151/018 EU/1/00/151/019 EU/1/00/151/020 EU/1/00/151/021 EU/1/00/151/022 EU/1/00/151/023 EU/1/00/151/024 
EU/1/00/151/014 EU/1/00/151/015 EU/1/00/151/016 EU/1/00/151/017 EU/1/00/151/018 EU/1/00/151/019 EU/1/00/151/020 EU/1/00/151/021 EU/1/00/151/022 EU/1/00/151/023 EU/1/00/151/024
Each Glustin 30 mg tablet contains 30 mg of pioglitazone (as hydrochloride). 
Ena 30-miligramska tableta Glustin vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
Broken bones have been reported commonly (may affect up to 1 in 10 people) in female patients taking Glustin and have also been reported in male patients (frequency cannot be estimated from the available data) taking Glustin. 
O zlomih so poročali tudi pri bolnikih, ki so se zdravili z zdravilom Glustin (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
Glustin 45 mg 
PODATKI V BRAILLOVI PISAVI Glustin 45 mg
Glustin 30 mg tablets pioglitazone 
IME ZDRAVILA Glustin 30 mg tablete pioglitazon
Each Glustin 45 mg tablet contains 45 mg of pioglitazone (as hydrochloride). 
Ena 45-miligramska tableta Glustin vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
EU/1/00/151/009 14 tablets EU/1/00/151/010 28 tablets EU/1/00/151/020 30 tablets EU/1/00/151/011 50 tablets EU/1/00/151/012 56 tablets EU/1/00/151/021 84 tablets EU/1/00/151/022 90 tablets EU/1/00/151/013 98 tablets 
EU/1/00/151/009 14 tablet EU/1/00/151/010 28 tablet EU/1/00/151/020 30 tablet EU/1/00/151/011 50 tablet EU/1/00/151/012 56 tablet EU/1/00/151/021 84 tablet EU/1/00/151/022 90 tablet EU/1/00/151/013 98 tablet
Glustin 45 mg tablets pioglitazone 
IME ZDRAVILA Glustin 45 mg tablete pioglitazon
Glustin 15 mg tablets pioglitazone 
IME ZDRAVILA Glustin 15 mg tablete pioglitazon
The tablets are white to off-white, round, flat and marked ‘45' on one face, ‘AD4' on the other. 
Tablete so bele ali skoraj bele barve, okrogle, ploščate, z oznako ‘45' na eni in AD4 na drugi strani.
EU/1/00/151/008 14 tablets EU/1/00/151/004 28 tablets EU/1/00/151/017 30 tablets EU/1/00/151/005 50 tablets EU/1/00/151/024 56 tablets EU/1/00/151/018 84 tablets EU/1/00/151/019 90 tablets EU/1/00/151/006 98 tablets 
EU/1/00/151/008 14 tablet EU/1/00/151/004 28 tablet EU/1/00/151/017 30 tablet EU/1/00/151/005 50 tablet EU/1/00/151/024 56 tablet EU/1/00/151/018 84 tablet EU/1/00/151/019 90 tablet EU/1/00/151/006 96 tablet
If you stop using Glustin, your blood sugar may go up. 
Če zdravilo Glustin prenehate jemati, se lahko raven krvnega sladkorja zviša, zato se pred prekinitvijo zdravljenja najprej posvetujte z zdravnikom.
- Glustin 15 mg tablets are white to off-white, round, convex tablets marked “15” on one face, “AD4” on the other. 
Tablete zdravila Glustin 15 mg so bele do sivobele barve, okrogle, izbočene, z oznako “15” na eni in “AD4” na drugi strani.
EU/1/00/151/007 14 tablets EU/1/00/151/001 28 tablets EU/1/00/151/014 30 tablets EU/1/00/151/002 50 tablets EU/1/00/151/023 56 tablets EU/1/00/151/015 84 tablets EU/1/00/151/016 90 tablets EU/1/00/151/003 98 tablets 
EU/1/00/151/007 14 tablet EU/1/00/151/001 28 tablet EU/1/00/151/014 30 tablet EU/1/00/151/002 50 tablet EU/1/00/151/023 56 tablet EU/1/00/151/015 84 tablet EU/1/00/151/016 90 tablet EU/1/00/151/003 98 tablet
Each Glustin 15 mg tablet contains 15 mg of pioglitazone (as hydrochloride). 
Ena 15-miligramska tableta Glustin vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).
The tablets are white to off-white, round, flat and marked ‘30' on one face, ‘AD4' on the other. 
Tablete so bele ali skoraj bele barve, okrogle, ploščate, z oznako ‘30' na eni in AD4 na drugi strani.
Your weight should be checked at regular intervals; if your weight increases, inform your doctor. 
Če se telesna masa poveča, o tem obvestite zdravnika.
Each tablet contains 45 mg of pioglitazone (as hydrochloride). 
Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
Each tablet contains 30 mg of pioglitazone (as hydrochloride). 
Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
The tablets are white to off-white, round, convex and marked ‘15' on one face, ‘AD4' on the other. 
Tablete so bele ali skoraj bele barve, okrogle, izbočene, z oznako ‘15' na eni in AD4 na drugi strani.
Heart failure has been experienced commonly (may affect up to 1 in 10 people) in patients taking Glustin in combination with insulin. 
Pri bolnikih, ki so jemali zdravilo Glustin v kombinaciji z insulinom, so pogosto (pri največ 1 od 10 bolnikov) poročali o pojavu srčnega popuščanja.
MANUFACTURER'S BATCH NUMBER 
ŠTEVILKA SERIJE Lot
Glustin 15 mg 
PODATKI V BRAILLOVI PISAVI Glustin 15 mg
nausea or vomiting). 
težave s spanjem (nespečnost)
14 January 2013 
14. januar 2013
The European Commission issued a decision on 14 January 2013. 
Evropska komisija je sklep izdala 14. januarja 2013.
Member States', in this instance Belgium, Bulgaria, Cyprus, Germany, Greece, Malta, Portugal, Romania and United Kingdom). 
(„zadevne države članice“, v tem primeru Belgija, Bolgarija, Ciper, Nemčija, Grčija, Malta, Portugalska, Romunija in Združeno kraljestvo).
It controls many body functions, mainly to do with growth and energy. 
Ščitnica nadzira številne telesne funkcije, predvsem funkcije, povezane z rastjo in energijo.
This could potentially lead to medication errors and pose a risk to public health. 
To bi lahko pripeljalo do napak pri uporabi zdravila in pomenilo tveganje za javno zdravje.
This is a procedure where one Member State (the ‘reference Member State', in this instance the Netherlands) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned 
To je postopek, v katerem ena država članica („referenčna država članica“, v tem primeru Nizozemska) ovrednoti zdravilo zato, da se izda dovoljenje za promet, ki bo veljalo v tej državi in drugih državah članicah
However, the Member States were not able to reach an agreement and the Dutch agency referred the matter to the CHMP for arbitration on 26 January 2012. 
Vendar države članice niso mogle doseči soglasja, zato je nizozemska agencija 26. januarja 2012 zadevo napotila odboru CHMP v arbitražni postopek.
It was to be available as oral drops (100 microgram/ml). 
Zdravilo naj bi bilo na voljo v obliki peroralnih kapljic (100 mikrogramov/ml).
On 18 October 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Levothyroxine Alapis. 
Evropska agencija za zdravila je 18. oktobra 2012 zaključila arbitražni postopek po nesoglasju med državami članicami Evropske unije (EU) glede izdaje dovoljenj za promet z zdravilom Levothyroxine Alapis.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Levothyroxine Alapis do not outweigh its risks, and the marketing authorisation cannot be granted in the Netherlands or in the following EU Member States: Belgium, Bulgaria, Cyprus, Germany, Greece, Malta, Portugal, Romania and United Kingdom. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agencije je ugotovil, da koristi zdravila Levothyroxine Alapis ne odtehtajo z njim povezanih tveganj ter da dovoljenja za promet ni mogoče izdati na Nizozemskem ali v naslednjih državah članicah EU: v Belgiji, Bolgariji, na Cipru, v Nemčiji, Grčiji, na Malti, Portugalskem, v Romuniji in Združenem kraljestvu.
Since the solution is highly concentrated and the active substance highly potent, there was an unacceptable risk of serious medication errors. 
Ker je raztopina visoko koncentrirana in zdravilna učinkovina zelo potentna, obstaja nesprejemljivo tveganje za napake pri uporabi zdravila.
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP agreed that there was a risk that the dropper used for delivery might deliver variable doses, and that large numbers of drops might be hard to count. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvenih razprav v Odboru, se je ta strinjal, da obstaja pri uporabi kapalke za odmerjanje tveganje za spremenljivo odmerjanje in da se lahko pri štetju tako velikega števila kapljic pojavijo napake.
In addition there were concerns over the safety of the combined long-term use of the ingredients ethanol and propylene glycol at the proposed concentrations, particularly in children. 
Poleg tega so izrazili tudi pomisleke glede varnosti dolgotrajne kombinirane uporabe sestavin etanol in propilenglikol pri predlaganih koncentracijah, zlasti pri otrocih.
Therefore the CHMP concluded that the benefits of Levothyroxine Alapis do not outweigh its risks, and that the marketing authorisation should not be granted in the concerned Member States. 
Odbor CHMP je zato zaključil, da koristi zdravila Levothyroxine Alapis ne odtehtajo z njim povezanih tveganj in da se dovoljenje za promet z zdravilom ne sme izdati v zadevnih državah članicah.
• conditions in which the thyroid gland is underactive (hypothyroidism, including diffuse non-toxic goitre) and so does not make enough thyroxine for the body's needs; 
• stanj, pri katerih je delovanje ščitnice zmanjšano (hipotiroidizem, vključno z difuzno netoksično golšo) in se zato ne proizvede dovolj tiroksina za potrebe telesa;
Thyroxine is normally produced in the body by the thyroid gland in the neck. 
Tiroksin v telesu običajno proizvaja žleza ščitnica v vratu.
Levothyroxine Alapis was intended to be used to treat: 
Zdravilo Levothyroxine Alapis je bilo namenjeno za zdravljenje:
• thyroid cancer. 
• raka ščitnice.
In addition, there remained concern over the safety of the long-term use of the ingredients ethanol and propylene glycol in children, and some groups of adults such as those with alcoholism. 
Prav tako niso izključili pomislekov glede varnosti dolgotrajne uporabe sestavin etanol in propilenglikol pri otrocih in nekaterih skupinah odraslih, na primer pri osebah, ki trpijo za alkoholizmom.
Why was Levothyroxine Alapis reviewed? 
Zakaj so zdravilo Levothyroxine Alapis ponovno pregledali?
The grounds for the referral were concerns raised by the UK related to the dropper insert as a proposed administration device, due to the large number of drops that may be required and concerns about its accuracy in delivering the required dose. 
Razlogi za napotitev so bili pomisleki Združenega kraljestva glede predlaganega pripomočka za dajanje, tj. kapalnega vložka, s katerim je treba odmeriti veliko število kapljic, in pomisleki v zvezi z natančnostjo odmerjanja.
What is Levothyroxine Alapis? 
Kaj je zdravilo Levothyroxine Alapis?
Alapis S.A. submitted an application for Levothyroxine Alapis to the Dutch medicines regulatory agency for a decentralised procedure. 
Družba Alapis S.A. je nizozemski regulatorni agenciji za zdravila predložila vlogo za pridobitev dovoljenja za promet z zdravilom Levothyroxine Alapis po decentraliziranem postopku.
The active substance in Levothyroxine Alapis, levothyroxine sodium, is a synthetic form of the hormone thyroxine. 
Natrijev levotiroksin, zdravilna učinkovina v zdravilu Levothyroxine Alapis, je sintetična oblika hormona tiroksina.
Levothryoxine Alapis is a medicine that contains the active substance levothyroxine sodium. 
Levothyroxine Alapis je zdravilo, ki vsebuje zdravilno učinkovino natrijev levotiroksin.
• a condition known as Hashimoto's thyroiditis, in which the immune system (the body's natural defences) attacks the thyroid causing it to swell and preventing it from working properly; 
• stanja, imenovanega Hashimotov tiroiditis, pri katerem imunski sistem (naravna obramba telesa)
30 mg Capsule, hard Oral use bottle (HDPE) 
Feraccru 30 mg kapsula, trda peroralna uporaba plastenka (HDPE) 56 kapsul
EU (MA) Number 
Številka EU (dovoljenja za promet z zdravilom)
Feraccru 
Jakost
This summary was last updated in 07-2012. 
Povzetek je bil nazadnje posodobljen 07-2012.
It is used to treat the following infections in adults: 
Uporablja se za zdravljenje naslednjih okužb pri odraslih:
‘Complicated' means that the infection is difficult to treat; 
„Zapletena“ pomeni, da je okužbo težko zdraviti.
The standard dose of Doribax is 500 mg every eight hours. 
Standardni odmerek zdravila Doribax je 500 mg vsakih osem ur.
The European Commission granted a marketing authorisation valid throughout the European Union for Doribax on 25 July 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Doribax, veljavno po vsej Evropski uniji, odobrila dne 25. julija 2008.
It works by attaching to certain types of protein on the surface of the bacteria cells. 
Deluje tako, da se veže na določene vrste beljakovin na površini bakterijskih celic.
Treatment usually continues for between five and 14 days, depending on the type and severity of the infection and the patient's response (10 to 14 days are usually needed in nosocomial pneumonia). 
Zdravljenje običajno traja od pet in 14 dni, odvisno od vrste in resnosti okužbe ter odziva bolnika (pri nozokomialni pljučnici je navadno potrebnih 10 do 14 dni).
Each infusion lasts for one hour, although some patients with nosocomial pneumonia may need infusions lasting four hours. 
Vsaka infuzija traja eno uro, čeprav bodo morda nekateri bolniki z nozokomialno pljučnico potrebovali infuzijo, ki bo trajala štiri ure.
This is a summary of the European public assessment report (EPAR) for Doribax. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Doribax.
The full EPAR for Doribax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Doribax je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
In all of the studies, the main measure of effectiveness was the number of patients whose infection 
Glavno merilo učinkovitosti v vseh študijah je bilo število bolnikov, pri katerih je bila okužba po zdravljenju ozdravljena.
This prevents the bacteria from building the walls that surround their cells, which kills the bacteria. 
To bakterijam prepreči tvorjenje sten okoli svojih celic, zaradi česar odmrejo.
The CHMP decided that Doribax's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Doribax večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The most common side effect with Doribax (seen in more than 1 patient in 10) is headache. 
Najpogostejši neželeni učinek zdravila Doribax (opažen pri več kot 1 od 10 bolnikov) je glavobol.
‘Nosocomial' means that the infection was caught in hospital, including pneumonia caused by the use of a ventilator (a machine that helps a 
„Nozokomialna“ pomeni, da je do okužbe prišlo v bolnišnici, vključno s pljučnico, povzročeno zaradi respiratorja (naprave, ki pomaga bolniku dihati);
For more information about treatment with Doribax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Doribax preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Doribax, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about Doribax 
Druge informacije o zdravilu Doribax
Before using Doribax, doctors should consider official guidance on the use of antibiotics. 
Preden zdravnik predpiše zdravilo Doribax, mora upoštevati uradne smernice za uporabo antibiotikov.
What benefit has Doribax shown during the studies? 
Kakšne koristi je zdravilo Doribax izkazalo med študijami?
It must not be used in patients who are severely allergic to other ‘beta-lactam' antibiotics, such as penicillins or cephalosporins. 
Ne smejo ga uporabljati bolniki s hudimi alergijami na beta-laktam antibiotike, kot so na primer penicilini ali cefalosporini.
Doribax is an antibiotic. 
Zdravilo Doribax je antibiotik.
Doribax was as effective as the other antibiotics in treating the infections: 
Zdravilo Doribax je bilo pri zdravljenju okužb enako učinkovito kot drugi antibiotiki:
It is available as a powder to be made up into a solution for infusion (drip into a vein). 
Na voljo je v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije v veno).
• nosocomial pneumonia (an infection of the lungs). 
• nozokomialne ali bolnišnične pljučnice (okužbe pljuč).
The list of bacteria against which Doribax is active can be found in the summary of product characteristics (also part of 
Seznam bakterij, proti katerim je zdravilo Doribax učinkovito, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
• complicated infections of the urinary tract (the structures that carry urine). 
• zapletene okužbe sečil (organov, ki prenašajo urin).
Doribax must not be used in people who are hypersensitive (allergic) to doripenem or to other carbapenems. 
Zdravila Doribax ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) doripenem ali druge karbapeneme.
The active substance in Doribax, doripenem, is an antibiotic that belongs to the group ‘carbapenems'. 
Zdravilna učinkovina zdravila Doribax , doripenem, je antibiotik, ki spada v skupino „karbapenemov“.
When treating nosocomial pneumonia, a dose of 1 g every eight hours infused over four hours may be considered for patients who have augmented renal clearance (where the kidneys clear the medicine from the body too quickly) or whose infection is caused by certain types of bacteria. 
Pri zdravljenju nozokomialne pljučnice pri bolnikih, pri katerih je ledvični očistek povečan (ledvice zdravilo izločijo iz telesa prehitro) ali pri katerih je okužbo povzročila določena vrsta bakterije, je možno 4-urno infundiranje zdravila v odmerku1 g vsakih osem ur.
Why has Doribax been approved? 
Zakaj je bilo zdravilo Doribax odobreno?
What is the risk associated with Doribax? 
Kakšna tveganja so povezana z zdravilom Doribax?
• complicated infections in the abdomen. 
• zapletene trebušne okužbe.